Key result
Semaglutide is associated with lower NNT estimates when evaluating broader clinical outcomes beyond major cardiovascular events alone.
Why the study?
NNTs calculated for primary trial endpoints may underestimate treatment value by ignoring other outcomes, motivating evaluation of semaglutide NNTs including broader clinical and payer-relevant endpoints.
Does semaglutide improve NNT estimates when broader clinically and payer-relevant outcomes are included in populations with overweight or obesity and established cardiovascular disease without diabetes?
Does semaglutide improve NNT estimates when broader clinically and payer-relevant outcomes are included in populations with overweight or obesity and established cardiovascular disease without diabetes?
Including broader clinically and payer-relevant outcomes beyond the primary endpoint yields lower NNT estimates for semaglutide in patients with overweight or obesity and established cardiovascular disease.
Answers are grounded in this paper and cite their sources.
Enhances semaglutide value for clinicians and payers; extends SELECT RCT data beyond MACE to composite outcomes.
INTRODUCTION: Number needed to treat (NNT), an outcome measure derived from the estimated risk results of clinical trials, is widely used to demonstrate value to stakeholders by identifying how many patients require treatment to avoid one event of interest. However, NNTs calculated for primary trial endpoints may underestimate a treatment's value by not considering other outcomes. In this secondary analysis of data from the SELECT cardiovascular (CV) outcomes trial, we aimed to determine the NNT for semaglutide for major adverse cardiovascular events (MACE), in addition to NNTs when other clinically and payer-relevant outcomes are included. METHODS: ] ≥ 6.5%, and a 5-point nephropathy composite). RESULTS: was 20 and 11, respectively. CONCLUSION: When clinically and payer-relevant outcomes from the SELECT trial are included in calculations of NNT, semaglutide was associated with greater risk reductions and lower estimates of NNT than for the primary endpoint alone. Our findings suggest that including the broader effects of semaglutide beyond the primary trial endpoint recognizes additional value to stakeholders.
No takes yet. Share an insight, caveat, or question.
Lübker et al. (2025) studied Overweight or obesity and established cardiovascular disease without diabetes. Semaglutide was evaluated on Number needed to treat (NNT) for major adverse cardiovascular events (MACE). Semaglutide was associated with lower estimates of NNT when broader clinically and payer-relevant outcomes were included compared to the primary endpoint alone.
Synapse has enriched 10 related papers. Consider them for comparative context: